Literature DB >> 29368268

A distributed delay approach for modeling delayed outcomes in pharmacokinetics and pharmacodynamics studies.

Shuhua Hu1, Michael Dunlavey2, Serge Guzy3, Nathan Teuscher2.   

Abstract

A distributed delay approach was proposed in this paper to model delayed outcomes in pharmacokinetics and pharmacodynamics studies. This approach was shown to be general enough to incorporate a wide array of pharmacokinetic and pharmacodynamic models as special cases including transit compartment models, effect compartment models, typical absorption models (either zero-order or first-order absorption), and a number of atypical (or irregular) absorption models (e.g., parallel first-order, mixed first-order and zero-order, inverse Gaussian, and Weibull absorption models). Real-life examples were given to demonstrate how to implement distributed delays in Phoenix® NLME™ 8.0, and to numerically show the advantages of the distributed delay approach over the traditional methods.

Keywords:  Atypical absorption models; Delay differential equations; Indirect response models; Transit compartment models

Mesh:

Substances:

Year:  2018        PMID: 29368268     DOI: 10.1007/s10928-018-9570-4

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  32 in total

1.  Incorporation of variability into the modeling of viral delays in HIV infection dynamics.

Authors:  H T Banks; D M Bortz; S E Holte
Journal:  Math Biosci       Date:  2003-05       Impact factor: 2.144

Review 2.  Pharmacokinetic strategies in deciphering atypical drug absorption profiles.

Authors:  Honghui Zhou
Journal:  J Clin Pharmacol       Date:  2003-03       Impact factor: 3.126

3.  Mathematical properties and parameter estimation for transit compartment pharmacodynamic models.

Authors:  James W T Yates
Journal:  Eur J Pharm Sci       Date:  2008-03-08       Impact factor: 4.384

4.  Implementation of dose superimposition to introduce multiple doses for a mathematical absorption model (transit compartment model).

Authors:  Jun Shen; Alison Boeckmann; Andrew Vick
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-05-04       Impact factor: 2.745

5.  Basic pharmacodynamic models for agents that alter the lifespan distribution of natural cells.

Authors:  Wojciech Krzyzanski; Juan Jose Perez-Ruixo; An Vermeulen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-06-13       Impact factor: 2.745

Review 6.  Concepts, properties, and applications of linear systems to describe distribution, identify input, and control endogenous substances and drugs in biological systems.

Authors:  D Verotta
Journal:  Crit Rev Biomed Eng       Date:  1996

7.  Modeling of delays in PKPD: classical approaches and a tutorial for delay differential equations.

Authors:  Gilbert Koch; Wojciech Krzyzanski; Juan Jose Pérez-Ruixo; Johannes Schropp
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-08-21       Impact factor: 2.745

8.  Arterial and venous pharmacokinetics of ropivacaine with and without epinephrine after thoracic paravertebral block.

Authors:  Manoj K Karmakar; Anthony M-H Ho; Bonita K Law; April S Y Wong; Steven L Shafer; Tony Gin
Journal:  Anesthesiology       Date:  2005-10       Impact factor: 7.892

9.  Mechanism-based pharmacodynamic modeling.

Authors:  Melanie A Felmlee; Marilyn E Morris; Donald E Mager
Journal:  Methods Mol Biol       Date:  2012

10.  Population pharmacokinetic modelling of tramadol using inverse Gaussian function for the assessment of drug absorption from prolonged and immediate release formulations.

Authors:  Nina Brvar; Tatjana Mateović-Rojnik; Iztok Grabnar
Journal:  Int J Pharm       Date:  2014-07-08       Impact factor: 5.875

View more
  4 in total

1.  R-praziquantel integrated population pharmacokinetics in preschool- and school-aged African children infected with Schistosoma mansoni and S. haematobium and Lao adults infected with Opisthorchis viverrini.

Authors:  Christine Falcoz; Serge Guzy; Jana Kovač; Isabel Meister; Jean Coulibaly; Somphou Sayasone; David Wesche; Yu-Wei Lin; Jennifer Keiser
Journal:  J Pharmacokinet Pharmacodyn       Date:  2022-01-13       Impact factor: 2.745

2.  Population Pharmacokinetic Analysis of Yimitasvir in Chinese Healthy Volunteers and Patients With Chronic Hepatitis C Virus Infection.

Authors:  Xiao-Duo Guan; Xian-Ge Tang; Ying-Jun Zhang; Hong-Ming Xie; Lin Luo; Dan Wu; Rui Chen; Pei Hu
Journal:  Front Pharmacol       Date:  2021-01-28       Impact factor: 5.810

3.  Exact solutions and equi-dosing regimen regions for multi-dose pharmacokinetics models with transit compartments.

Authors:  F Hof; L J Bridge
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-10-10       Impact factor: 2.745

4.  Pharmacokinetic Model Analysis of Supralingual, Oral and Intravenous Deliveries of Mycophenolic Acid.

Authors:  Xiuqing Gao; Lei Wu; Robert Y L Tsai; Jing Ma; Xiaohua Liu; Diana S-L Chow; Dong Liang; Huan Xie
Journal:  Pharmaceutics       Date:  2021-04-17       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.